Development of highly stable and de-immunized versions of recombinant alpha interferon: promising candidates for the treatment of chronic and emerging viral diseases
- Giorgetti, Sofia Inés
- Etcheverrigaray, Marina
- Terry, Frances
- Martin, William
- De Groot, Anne Searls
- Ceaglio, Natalia Analia
- Oggero Eberhardt, Marcos Rafael
- Mufarrege, Eduardo Federico
DOIAbstract
Human interferon alpha (hIFN-α) administration constitutes the current FDA approved therapy for chronic Hepatitis B and C virus infections. Additionally, hIFN-α treatment efficacy was recently demonstrated in patients with COVID-19. Thus, hIFN-α constitutes a therapeutic alternative for those countries where vaccination is inaccessible and for people who did not respond effectively to vaccination. However, hIFN-α2b exhibits a short plasma half-life resulting in the occurrence of severe side effects. To optimize the cytokine's pharmacokinetic profile, we developed a hyperglycosylated IFN, referred to as GMOP-IFN. Given the significant number of reports showing neutralizing antibodies (NAb) formation after hIFN-α administration, here we appli...
Add to ORKG